Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.
Our dream is to provide life-long cures for patients suffering from serious diseases.
The Beam Team Is:
• A community of fearless innovators
• Rigorous and honest in our research
• Listening with open minds
• Committed to each other
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $402M
Founded date: 2017
Investors 9
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.02.2020 | IPO | $180M | - |
| 07.03.2019 | Series B | $135M | - |
| 14.05.2018 | Series A | $87M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадил... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной сви... | incrussia.... |
| 17.08.2023 | The 30 young leaders who are forging a new future for the he... | Your browser does not support the video element. This story is available exclusively to Insider subs... | businessin... |
| 30.11.2022 | Beam Therapeutics to Participate in the BofA Securities 2022... | CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. BEAM, a biotechnology com... | einpresswi... |
| 29.12.2021 | TalkPython: лучшие пакеты Python по итогам 2021 года... | На КДПВ в гостях у TalkPython вы видите Гвидо ван Россума — создателя Python, Марка Шеннона, план ус... | habr.com/r... |
| 07.02.2020 | Beam Therapeutics raises $180M in IPO | The company had filed to go public in September, aiming at a $100 million IPO. J.P. Morgan, Jefferei... | medcitynew... |
| 06.02.2020 | Beam Therapeutics raises $180 million in IPO | Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an init... | statnews.c... |
| 06.02.2020 | Beam Therapeutics IPO Raises $180M After Nearly Doubling Sha... | - | fprimecapi... |
| 27.01.2020 | Gene editing biotech Beam Therapeutics sets terms for $100 m... | - | fprimecapi... |
| 30.09.2019 | Gene editing company Beam Therapeutics aims for $100M IPO | The company declined to comment because it is in a quiet period in connection with the filing. Beam’... | medcitynew... |
| 07.05.2019 | Verve Therapeutics aims to tackle heart disease through gene... | In terms of financing, the company has raised a $58.5 million Series A round, led by GV and with par... | medcitynew... |
Show more